Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

If all goes well, CTP-543 could be ready for filing in early 2023, but even so it looks set to reach the AA market well behind Eli Lilly, which reported positive phase 3 results with its JAK 1/2 ...

Lilly's stock went on a tear in the beginning of 2023, with the company's shares doubling as investors bet on the drug's popularity. The stock stumbled in October last year, after Zepbound's sales ...